Biomedical researches is a biomedical research project that emerged at the end of 2013, and its origin is my great passion for biomedical research focused on the cure of serious or incurable diseases.
NANOBICAR for tuberculosis
(chosen by European Commission in 2024)
NanoBiCar is developing a nanotechnology-based immunotherapy that reprograms the immune system to recognize and eliminate hard-to-reach intracellular and extracellular bacteria.
It is estimated that 20% of global mortality is associated with bacterial infections. The current treatment is based on the use of antibiotics, but nonspecific effects, difficulty in reaching intracellular bacteria, and the generation of antimicrobial resistance limit its effectiveness. Tuberculosis (TB) is the leading cause of mortality due to a single infectious agent: Mycobacterium tuberculosis (Mtb). Multidrug-resistant TB (MDR-TB) is a major threat to global health security. A quarter of the population is latently infected with Mtb, many of them MDR strains, so preventing new cases of this growing reservoir is a priority.
Immunotherapy is an alternative option, but its effectiveness is based on the immune response capacity of a compromised host. NanoBiCar’s long-term vision is to revolutionize the current treatment of bacterial infections with a groundbreaking and innovative immunotherapeutic approach, overcoming many of the problems associated with treatment, with potential application beyond this field. Using TB as a proof of concept, three immunotherapeutic platforms, using mRNAs encapsulated in lipid nanoparticles, not tested in bacterial diseases, will be used to eliminate intra (IC) and extracellular (EC) bacteria.
These immunotherapeutic methods are safe, economical, accessible, ready-to-use, and specific, targeting latent/acute/chronic infections, without generating resistance and suitable for use in high-burden, low-resource settings; effective regardless of the antibiotic resistance of the strain and its niche (IC or EC), the genetic background of the host, and the degree of immunocompetence.
Here below, in this link, you can see the website of the project:
https://nanobicar.eu/
More information:
https://nanobicar.eu/about/
And about the Consortium:
https://nanobicar.eu/consortium/
ULISES PROJECT for pancreatic cancer
(chosen by European Commission in February, 2020)
I'm the author of the original technical project on which the Ulises Project is based, as well as Principal Investigator (PI) of the Ulises Project.
This project is based on a new therapy (immunotherapy) invented by me, by means of delivery of plasmid DNA to transform tumor cells into immunologically incompatible cells, thus provoking the strongest possible attack of the immune system over them, without the use of drugs, chemotherapy, radiotherapy, transplants, etc., thus providing, at the same time, a much better quality of life to the patient, since this new immunotherapy is hoped to cause little or null side effects.
This new immunotherapy is included in my original technical project, which, moreover, includes: immunologic strategy design, genetic design, nanoparticles (including ligands to be used), oncology strategy, biochemistry, Tumor Infiltrating Lymphocytes (TIL) generated around the tumor microenvironment by the immune system, which will lead to an “immunological-memory” avoiding future relapses (vaccine-like effect), "Plans B", etc.
Although Ulises Project is a project for the cure of pancreatic cancer, it's also easily adaptable to any cancer type with minimal changes, and was chosen by the European Commission in February, 2020. It's endowed with a budget of 3 million euros, it started in October, 2020, and its duration will be 3 years.
To make this new immunotherapy a reality I gathered a team of great experts, thus forming an important Consortium containing 10 entities (including me), and belonging to 5 contries (Spain, Germany, Italy, Belgium and The Netherlands).
I am also telecommunications engineer and economist, I work in Telefónica since 1999, in Madrid (Spain), and I am a computer specialist, expert in different programming languages. During the Ulises project, I will be involved in immunology, in order to decide the most optimal immunological setup to be used to improve the immune response over tumor cells. as well as I will also contribute to other areas (genetic design, nanoparticles design, etc.) actively participating in technical and scientific discussions, giving feedback, generating ideas, conducting bibliographic research, contributing to reporting, dissemination and communication of the project results.
ULISES has been successful in-vitro.
Currently, there are several papers in preparation.
We hope to be able to continue our project.
Here below, in this link, you can see the website of the project:
https://ulises-project.eu/
And we are also in:
ULISES PRESENTATION VIDEO
https://www.youtube.com/watch?v=btrWYZGOzlE
INTERVIEW IN SPANISH TELEVISION (TVE) - CHANNEL "LA 2", PROGRAM "LA AVENTURA DEL SABER", DATE: MAY, 26th, 2021
https://www.rtve.es/alacarta/videos/la-aventura-del-saber/aventura-del-saber-proyecto-ulises-victor-pallaruelo/5917890/
NOTE: My COVID project is currently at a standstill due to lack of funds.
INTERVIEW IN SPANISH RADIO - RADIO 5 (FROM RADIO NACIONAL DE ESPAÑA) - PROGRAM "ENTRE PROBETAS", DATE: JUNE,15th, 2021
https://mediavod-lvlt.rtve.es/resources/TE_SENTREP/mp3/1/0/1623744396801.mp3
(It goes from minute 05:55 to 17:06)
Although I am talking about my biomedical projects (ULISES, Covid), this is a more intimate interview, since it focuses on aspects such as my origins in biomedical research, my future projects, etc...
RADIO 5 (FROM RADIO NACIONAL DE ESPAÑA) - PROGRAM "EL LABORATORIO DE JAL", DATES: SEPTEMBER, 13th, 2021 at 16:22h, and SEPTEMBER, 16th, 2021, at 21:37h
https://mediavod-lvlt.rtve.es/resources/TE_SLABJAL/mp3/6/3/1631520709036.mp3
Scientific pill dedicated to ULISES project, highlighting its most important aspects.
A CHAT WITH VICTOR PALLARUELO, DATE: MAY, 27th, 2024
https://ulises-project.eu/news/meet-the-team-a-chat-with-victor-pallaruelo/
ASSESSMENT OF THE EFFICACY OF A MONOCLONAL ANTIBODY AGAINST PANCREATIC TUMOUR CELLS BY COMPLEMENT-DEPENDENT CYTOTOXICITY ASSAY
7th European Congress of Immunology (ECI) - Dublin (Ireland) - 01-04 September 2024 · 11 oct. 2024
These results demonstrate the efficacy of ULISES therapy in vitro.
CONTACT
Esta dirección de correo electrónico está siendo protegida contra los robots de spam. Necesita tener JavaScript habilitado para poder verlo.